NasdaqGS - Delayed Quote • USD
Bolt Biotherapeutics, Inc. (BOLT)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:22 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,876.0000
7,876.0000
5,729.0000
1,260.0000
231.0000
Operating Expense
84,072.0000
84,072.0000
96,050.0000
94,048.0000
49,413.0000
Operating Income
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
Net Non Operating Interest Income Expense
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
Other Income Expense
--
--
--
-6,084.0000
-11,745.0000
Pretax Income
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Net Income Common Stockholders
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Diluted NI Available to Com Stockholders
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Basic EPS
-1.83
--
-2.36
-2.97
-1.91
Diluted EPS
-1.83
--
-2.36
-2.97
-1.91
Basic Average Shares
37,811.9840
--
37,358.4250
33,196.7120
31,846.6980
Diluted Average Shares
37,811.9840
--
37,358.4250
33,196.7120
31,846.6980
Total Operating Income as Reported
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
Total Expenses
84,072.0000
84,072.0000
96,050.0000
94,048.0000
49,413.0000
Net Income from Continuing & Discontinued Operation
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Normalized Income
-69,197.0000
-69,197.0000
-88,098.0000
-92,507.0000
-48,983.0000
Interest Income
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
Net Interest Income
6,999.0000
6,999.0000
2,223.0000
281.0000
199.0000
EBIT
-76,196.0000
-76,196.0000
-90,321.0000
-92,788.0000
-49,182.0000
EBITDA
-74,342.0000
-74,342.0000
-88,655.0000
-91,595.0000
-48,571.0000
Reconciled Depreciation
1,854.0000
1,854.0000
1,666.0000
1,193.0000
611.0000
Net Income from Continuing Operation Net Minority Interest
-69,197.0000
-69,197.0000
-88,098.0000
-98,591.0000
-60,728.0000
Total Unusual Items Excluding Goodwill
--
--
--
-6,084.0000
-11,745.0000
Total Unusual Items
--
--
--
-6,084.0000
-11,745.0000
Normalized EBITDA
-74,342.0000
-74,342.0000
-88,655.0000
-85,511.0000
-36,826.0000
12/31/2020 - 2/5/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACHL Achilles Therapeutics plc
0.7600
-2.69%
NXTC NextCure, Inc.
1.3500
+4.65%
CMPX Compass Therapeutics, Inc.
1.4500
-2.03%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
SNSE Sensei Biotherapeutics, Inc.
1.0200
-1.92%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
MRUS Merus N.V.
45.04
+0.24%
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
HOWL Werewolf Therapeutics, Inc.
6.75
+8.70%